Beacon Biosignals Secures $86M to Revolutionize Brain Disorder Treatment
November 18, 2025, 9:34 pm
Beacon Biosignals landed $86M in Series B funding. They plan to use it to improve diagnostics and treatment using AI. Their neurotechnology targets brain disorders. The funding helps them expand and accelerate discovery. This positions them as leaders in precision neuroscience.
Boston-based Beacon Biosignals has secured $86 million in Series B funding. The investment will fuel the company's mission to revolutionize diagnostics and precision medicine for brain disorders. The funding round signals strong investor confidence in Beacon's innovative neurotechnology platform.
Beacon Biosignals is developing AI-driven diagnostics. Their technology aims to provide more accurate and timely insights into neurological and psychiatric conditions. The company's platform uses advanced algorithms to analyze brain activity data. This helps identify biomarkers for various disorders.
The Series B funding was oversubscribed. This indicates high demand and investor enthusiasm. Innoviva and Google Ventures (GV) co-led the round. Other participants included Nexus NeuroTech Ventures, S32, and Catalio Capital Management. Takeda, General Catalyst, Logos Capital, Casdin Capital, and Indicator Ventures also contributed. The new funding brings Beacon's total capital raised to over $121 million.
The company will use the funds to scale its technology. They also plan to expand their operations. A key focus is accelerating neurobiomarker discovery. Another priority is broadening clinical adoption of their platform. This strategic allocation of capital is expected to drive significant growth.
Dr. Jacob Donoghue leads Beacon Biosignals as CEO and co-founder. His vision is to make brain function measurable and actionable. He believes AI can unlock new insights into brain health. This can improve drug development and patient care.
Beacon Biosignals uses FDA-cleared wearable EEG technology. This technology captures real-world neural data. The data is then analyzed using advanced AI. This approach enables breakthroughs in neurology, psychiatry, and sleep medicine.
The Beacon platform provides clinicians with objective measures of brain function. These measures can accelerate research. They can also improve diagnostics. The platform also guides the development of new treatments.
The company's Waveband device directly measures brain electrical activity. It does this during both sleep and wakefulness. The device captures ecologically valid data. This data helps track brain function over time.
Beacon has created a foundation model of brain activity. This model is trained on millions of hours of EEG data. It can uncover early disease signatures. It can also predict treatment response.
Beacon partners with leading biopharmaceutical companies. These partners include Takeda, UCB, and Mineralys. They also collaborate with Syndeio and other industry leaders. These partnerships help accelerate drug development.
Beacon recently acquired CleveMed's home sleep-testing technology. This acquisition adds new capabilities. It now includes airflow, oxygen saturation, and respiratory monitoring. This creates a comprehensive platform for analyzing sleep and brain function.
Sleep is a central focus of the Beacon platform. Many neurological and psychiatric disorders affect sleep patterns. This makes sleep data essential for diagnostics. It is also critical for therapeutic development. Conditions like Parkinson's, Alzheimer's, depression, and sleep apnea show distinctive sleep patterns.
Beacon believes precision neuroscience can transform CNS disorders. They aim to have the same impact as biomarkers in oncology. Real-world sleep and EEG monitoring are key.
Anthony Philippakis from GV highlights the lack of objective biomarkers in neurology. He believes Beacon's platform brings precision to brain health. Pavel Raifeld from Innoviva sees Beacon building a category-defining business. They are connecting brain data to drug development and clinical care.
Beacon Biosignals is poised for significant growth. Their technology addresses a critical need in brain disorder treatment. The company's innovative platform and strategic partnerships position them as leaders in the field. The new funding will accelerate their mission to improve patient outcomes. The future of brain health is looking brighter.
Beacon Biosignals Lands $86M to Transform Brain Disorder Treatment
Boston-based Beacon Biosignals has secured $86 million in Series B funding. The investment will fuel the company's mission to revolutionize diagnostics and precision medicine for brain disorders. The funding round signals strong investor confidence in Beacon's innovative neurotechnology platform.
AI-Powered Diagnostics
Beacon Biosignals is developing AI-driven diagnostics. Their technology aims to provide more accurate and timely insights into neurological and psychiatric conditions. The company's platform uses advanced algorithms to analyze brain activity data. This helps identify biomarkers for various disorders.
Investment Details
The Series B funding was oversubscribed. This indicates high demand and investor enthusiasm. Innoviva and Google Ventures (GV) co-led the round. Other participants included Nexus NeuroTech Ventures, S32, and Catalio Capital Management. Takeda, General Catalyst, Logos Capital, Casdin Capital, and Indicator Ventures also contributed. The new funding brings Beacon's total capital raised to over $121 million.
Funding Allocation
The company will use the funds to scale its technology. They also plan to expand their operations. A key focus is accelerating neurobiomarker discovery. Another priority is broadening clinical adoption of their platform. This strategic allocation of capital is expected to drive significant growth.
Leadership and Vision
Dr. Jacob Donoghue leads Beacon Biosignals as CEO and co-founder. His vision is to make brain function measurable and actionable. He believes AI can unlock new insights into brain health. This can improve drug development and patient care.
Wearable EEG Technology
Beacon Biosignals uses FDA-cleared wearable EEG technology. This technology captures real-world neural data. The data is then analyzed using advanced AI. This approach enables breakthroughs in neurology, psychiatry, and sleep medicine.
Objective Measures of Brain Function
The Beacon platform provides clinicians with objective measures of brain function. These measures can accelerate research. They can also improve diagnostics. The platform also guides the development of new treatments.
Waveband Device
The company's Waveband device directly measures brain electrical activity. It does this during both sleep and wakefulness. The device captures ecologically valid data. This data helps track brain function over time.
Foundation Model of Brain Activity
Beacon has created a foundation model of brain activity. This model is trained on millions of hours of EEG data. It can uncover early disease signatures. It can also predict treatment response.
Strategic Partnerships
Beacon partners with leading biopharmaceutical companies. These partners include Takeda, UCB, and Mineralys. They also collaborate with Syndeio and other industry leaders. These partnerships help accelerate drug development.
CleveMed Acquisition
Beacon recently acquired CleveMed's home sleep-testing technology. This acquisition adds new capabilities. It now includes airflow, oxygen saturation, and respiratory monitoring. This creates a comprehensive platform for analyzing sleep and brain function.
Focus on Sleep
Sleep is a central focus of the Beacon platform. Many neurological and psychiatric disorders affect sleep patterns. This makes sleep data essential for diagnostics. It is also critical for therapeutic development. Conditions like Parkinson's, Alzheimer's, depression, and sleep apnea show distinctive sleep patterns.
Transformative Impact
Beacon believes precision neuroscience can transform CNS disorders. They aim to have the same impact as biomarkers in oncology. Real-world sleep and EEG monitoring are key.
Expert Opinions
Anthony Philippakis from GV highlights the lack of objective biomarkers in neurology. He believes Beacon's platform brings precision to brain health. Pavel Raifeld from Innoviva sees Beacon building a category-defining business. They are connecting brain data to drug development and clinical care.
Future Outlook
Beacon Biosignals is poised for significant growth. Their technology addresses a critical need in brain disorder treatment. The company's innovative platform and strategic partnerships position them as leaders in the field. The new funding will accelerate their mission to improve patient outcomes. The future of brain health is looking brighter.